June 23, 2021
InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation
Media
June 22, 2021
Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 22, 2021
Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 21, 2021
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
June 21, 2021
Doctrin raises €13 million to accelerate international expansion
June 17, 2021
BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma
June 17, 2021
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 16, 2021
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 14, 2021
Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434
June 14, 2021
Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
